Eli Lilly (LLY) Liabilities from Discontinued Operations (2018)
Eli Lilly posted quarterly Liabilities from Discontinued Operations of 2742300000.0 for Q4 2018.
Eli Lilly (LLY) has 1 years of Liabilities from Discontinued Operations data on file, last reported at 2742300000.0 in Q4 2018.
- For the quarter ending Q4 2018, Liabilities from Discontinued Operations changed N/A year-over-year to 2742300000.0; the trailing twelve-month figure through Dec 2018 stood at 2742300000.0 (changed N/A YoY), and the FY2018 full-year result was 2742300000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q4 2018 stood at 2742300000.0.
- Across five years, Liabilities from Discontinued Operations topped out at 2742300000.0 in Q4 2018 and bottomed at 2742300000.0 in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 2.74 Bn |
| Dec 31, 2018 | 2.74 Bn |